

Partnering Activity Update

November 01, 2022

Cautionary Notes

Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable.

Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to:

- (i) failures in new product development***
- (ii) changes in general economic conditions due to reform of medical insurance system***
- (iii) failures in obtaining the expected results due to effects of competing products or generic drugs***
- (iv) infringements of the Company's intellectual property rights by third parties***
- (v) stagnation of product supply from the delay in production due to natural disasters, fires and so on***
- (vi) onset of new side effect of post-licensure medical product***
- and, (vii) currency exchange rate fluctuations and interest rate trend.***

Information about pharmaceutical products (including products currently in development) included in this document is not intended to constitute an advertisement of medical advice.

Partnering Activity (2010~) (1)

As of Oct 28, 2022

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Sep 2010	KYPROLIS (Carfilzomib)	Multiple Myeloma (Proteasome inhibitor)	L	L	Amgen, USA (in-license/JP)
Sep 2011	CORALAN (Ivabradine)	Chronic Heart Failure (HCN channel blocker)	L	L	Servier, France (in-license/JP)
	PARSABIV (Etelcalcetide)	Secondary Hyperparathyroidism (Calcium sensing receptor agonist)	L	L	Amgen, USA (in-license/JP)
	OPDIVO (Nivolumab)	Melanoma, NSCLC, RCC, Hodgkin's Lymphoma, H&N cancer, Malignant Pleural Mesothelioma, Urothelial Carcinoma, Colorectal Cancer (dMMR or MSI-H), Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma (Anti-PD-1 mAb)	L	L	BMS, USA (out-license/ except JP, KR & TW)
	ORENCIA (Abatacept)	Rheumatoid Arthritis, Juvenile Idiopathic Arthritis (T cell activation inhibitor)	L	L	BMS, USA (in-license/JP)
Apr 2013	ONGENTYS (Opicapone)	Wearing-off phenomenon in Parkinson's Disease (COMT inhibitor)	L	L	Bial, Portugal (in-license/JP)
Oct 2013	DEMSEER (Metyrosine)	Status of Catecholamine Excess Secretion in Pheochromocytoma (Tyrosine hydroxylase inhibitor)	L	L	Bausch Health, USA (in-license/JP)

The most advanced clinical phase is described.



ONO PHARMACEUTICAL CO.,LTD.

Partnering Activity (2010~) (2)

As of Oct 28, 2022

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Dec 2013	FORXIGA (Dapagliflozin)	Type 2 Diabetes, Type 1 Diabetes, Chronic Heart Failure, Chronic Kidney Disease (SGLT-2 inhibitor)	L	L	AstraZeneca, UK (in-license/JP)
Jul 2014	YERVOY (Ipilimumab)	Melanoma, RCC, Colorectal Cancer (MSI-H), NSCLC, Malignant Pleural Mesothelioma, Esophageal Cancer (Anti-CTLA-4 mAb)	L	L	BMS, USA (in-license/JP, KR & TW)
	ONO-4482 (Relatlimab)	Melanoma (Anti-LAG-3 mAb)	I/II	L★	
	ONO-4686 BMS-986207	Solid Tumor (Anti-TIGIT mAb)	I/II	I/II	
	ONO-7122	Solid Tumor (TGF-β inhibitor)	I	I	
Jul 2014	OPALMON (Limaprost α-CD)	Lumber Spinal Canal Stenosis (oral PGE1 analogue)	L	L	Meiji Seika Pharma, Japan (out-license/THA)
Mar 2016	ONO-9054 (Sepetaprost)	Glaucoma, Ocular Hypertension (FP/EP3 dual receptor agonist)	II	II	Santen Pharmaceutical, Japan (out-license/Global)

The most advanced clinical phase is described.

★ : fixed-dose combination of nivolumab and relatlimab



ONO PHARMACEUTICAL CO.,LTD.

Partnering Activity (2010~) (3)

As of Oct 28, 2022

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
May 2017	MEKTOVI (Binimetinib) BRAFTOVI (Encorafenib)	BRAF-mutant Melanoma (MEK inhibitor・BRAF inhibitor)	L	L	Pfizer, USA (in-license/JP & KR)
		BRAF-mutant Colorectal Cancer (MEK inhibitor・BRAF inhibitor)	L	L (BRAFTOVI)	
		BRAF-mutant Thyroid Cancer (MEK inhibitor・BRAF inhibitor)	II	—	
Aug 2017	JOYCLU (Diclofenac etalhyaluronate)	Osteoarthritis (Hip joint, Knee joint) (Combined drug of hyaluronic acid and NSAID)	L	II	Seikagaku, Japan (in-license/JP)
Jul 2019	ONO-7913 (Magrolimab)	TP53-mutant Acute Myeloid Leukemia (Anti-CD47 mAb)	III	III	Gilead Sciences, USA (in-license/JP, KR, TW & ASEAN)
		Acute Myeloid Leukemia (Anti-CD47 mAb)	—	III	
		Solid Tumor (Anti-CD47 mAb)	I	II	
		Myelodysplastic Syndromes (Anti-CD47 mAb)	I	III	
		Pancreatic Cancer (Anti-CD47 mAb)	I	—	
		Colorectal Cancer (Anti-CD47 mAb)	I	—	

The most advanced clinical phase is described.



ONO PHARMACEUTICAL CO.,LTD.

Partnering Activity (2010~) (4)

As of Oct 28, 2022

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Oct 2020	ONO-2017 (Cenobamate)	Primary generalized tonic-clonic Seizures, Partial-onset Seizures (voltage-gated sodium currents inhibitor, γ -aminobutyric acid (GABA _A) ion channel modulator)	III	L	SK Biopharmaceuticals, Korea (in-license/JP)
Dec 2020	ONO-7018 (CTX-177)	Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor)	–	I	Chordia Therapeutics, Japan (in-license/Global)
Feb 2021	ONO-7119 (Atamparib)	Solid Tumor (Poly ADP-ribose polymerase 7 (PARP7) inhibitor)	I	I	Ribon Therapeutics, USA (in-license/JP, KR, TW & ASEAN)

The most advanced clinical phase is described.




ONO PHARMACEUTICAL CO.,LTD.

Collaboration with BMS for OPDIVO®

**Start collaboration
in May 2005**


**Expand collaboration
in Sep 2011**




Strategic Alliance with BMS in JP, KR & TW

- To Strengthen Immuno-oncology Portfolio
- To Accelerate Combination Therapies

Co-development




Co-promotion




Development cost share

Profit/loss allocation




Collaboration with BMS for ORENCIA®

- Biologic Inhibiting Upstream Inflammation in RA



Collaboration with AstraZeneca for FORXIGA®

- The First SGLT-2 Inhibitor in the World for Type-2 Diabetes
- In 2019, additional approval for Type-1 diabetes in Japan
- In 2020, additional approval for Chronic Heart Failure in Japan
- In 2021, additional approval for Chronic Kidney Disease in Japan





ONO PHARMACEUTICAL CO.,LTD.

Dedicated to the Fight against Disease and Pain